Table 1.

Pharmaceutical agents under development for the treatment of NASH

Therapeutic agent	Manufacturer	Target	Proposed mode of action
BMS986036	Bristol-Myers Squibb	Modulation of FGF21 metabolism	Improvement of hepatic lipid and glucose metabolism; anti-inflammatory
Cenicriviroc	Tobira Therapeutics	CCR2 and CCR5	Inhibition of CCR2- and CCR5-mediated monocyte/macrophage infiltration and inflammation
Elafibranor	Genfit	Modulation of hepatic PPARα and PPARδ pathways	Stimulation of NEFA oxidation; improvement of lipid and glucose metabolism; prevention of inflammation
Emricasan	Conatus Pharmaceuticals	Caspase pathways (pan-caspase inhibitor)	Inhibition of fibrosis by blocking caspase protease activation and apoptosis pathways
GR-MD-02	Galectin Therapeutics	Galectin-3 inhibitor	Prevention of inflammation and fibrosis
Obeticholic acid	Intercept Pharmaceuticals	FXR agonist	Regulation of hepatic glucose and lipid metabolism
Px-104	Phenex Pharmaceuticals/ Gilead Sciences	FXR agonist	Regulation of hepatic glucose and lipid metabolism
Simtuzumab	Gilead Sciences	LOXL2 enzyme activity	Inhibition of fibrosis by a LOXL2 monoclonal antibody

Agents are listed in alphabetical order

FXR, Farnesoid X receptor; LOXL2, Lysyl oxidase-like 2